Revenue
2018
2019
2020
2021
2022
2023
2024
2025
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.27B | $20.31B | $20.32B | $18.31B | $16.12B | $16.12B | $11.09B | $9.41B |
| Gross profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B | $7.73B | $7.54B | $8.30B | $10.71B | $10.65B | $9.52B | $9.06B | $7.37B | $5.97B | $4.88B |
| Research & development | $1.01B | $998.0M | $953.0M | $838.0M | $967.0M | $997.0M | $1.01B | $1.21B | $1.43B | $1.36B | $1.09B | $951.0M | $825.0M | $786.0M | $581.0M |
| Operating income | $2.16B | −$303.0M | $433.0M | −$2.20B | $1.72B | −$3.57B | −$443.0M | −$1.64B | $1.65B | $2.21B | $3.11B | $3.87B | $2.40B | $1.15B | $2.40B |
| EBITDAderived | $3.16B | $756.0M | $1.59B | −$889.0M | $3.05B | −$2.02B | $1.28B | $205.0M | $3.29B | $3.91B | $4.18B | $4.85B | $3.31B | $1.64B | $2.89B |
| Net income | $1.41B | −$1.64B | −$559.0M | −$2.45B | $417.0M | −$3.99B | −$999.0M | −$2.15B | $1.27B | $1.96B | $2.76B | $3.33B | $2.00B | $609.0M | $1.91B |
| Basic EPSper diluted share | $1.23 | -$1.45 | -$0.50 | -$2.20 | $0.38 | -$3.64 | -$0.91 | -$2.35 | $1.49 | $2.25 | $3.10 | $3.72 | $2.29 | $0.78 | $2.49 |
| Diluted EPSper diluted share | $1.21 | -$1.45 | -$0.50 | -$2.20 | $0.38 | -$3.64 | -$0.91 | -$2.35 | $1.49 | $2.25 | $3.09 | $3.67 | $2.23 | $0.75 | $2.36 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 | Shields MatthewEVP, Global Operations | SellOrdinary Shares | 10.0K | $32.19 | $321.5K | 0 |
| Jun 11, 2026Form 4 · 10b5-1 | Kalif Eliyahu SharonEVP, Chief Financial Officer | SellOrdinary Shares | 106.6K | $34.10 | $3.63M | 65.6K |
| Jun 5, 2026Form 4 · 10b5-1 | Francis Richard DPresident and CEO | SellOrdinary Shares | 6.2K | $34.35 | $211.4K | 1.18M |
| Jun 3, 2026Form 4 · 10b5-1 | Shields MatthewEVP, Global Operations | SellOrdinary Shares | 16.2K | $32.87 | $532.3K | 10.0K |
| May 14, 2026Form 4 · 10b5-1 | Lippman EvanEVP, Business Development | SellOrdinary Shares | 35.9K | $35.58 | $1.28M | 44.2K |